Incidence Rate of Injection-Site Granulomas Resulting from the Administration of Luteinizing Hormone-Releasing Hormone Analogues for the Treatment of Prostatic Cancer
Yonsei Medical Journal
;
: 421-424, 2007.
Article
in English
| WPRIM
| ID: wpr-71499
ABSTRACT
PURPOSE:
Granulomas resulting from the administration of luteinizing hormone-releasing hormone analogues (LH-RH analogues) are thought to be very rare. We report on our clinical experience with injection-site granulomas that result from the administration of LH-RH analogues, and we evaluate the incidence rate of these granulomas. MATERIALS ANDMETHODS:
We used the clinical records of 118 patients who were administered LH-RH analogues in 2005. We describe the clinical data of patients who experienced injection-site granulomas and evaluated the incidence rate.RESULTS:
Five patients demonstrated injection-site granulomas due to LH-RH analogue administration. The incidence rate was 4.2% (5 of 118 patients). Most of the granulomas occurred after the first or second administration of 11.25mg of leuprorelin acetate.CONCLUSION:
The occurrence of granulomas resulting from the administration of LH-RH analogues was thought to be very rare. Our study, however, revealed a higher incidence rate than expected, especially for leuprorelin acetate.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prostatic Neoplasms
/
Antigens, Differentiation, Myelomonocytic
/
Antigens, CD
/
Gonadotropin-Releasing Hormone
/
Leuprolide
/
Goserelin
/
CD3 Complex
/
Antineoplastic Agents, Hormonal
/
Granuloma
/
Injections, Subcutaneous
Type of study:
Incidence study
Limits:
Aged
/
Aged80
/
Humans
/
Male
Language:
English
Journal:
Yonsei Medical Journal
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS